ConductScience.org, home

Comparison · NCT02246218-sae

RAVICTI: Age 2 Months to < 2 Years vs RAVICTI: Age 0 to <2 Months: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. RAVICTI: Age 2 Months to < 2 Years vs RAVICTI: Age 0 to <2 Months: serious adverse events. Trial comparisons, record NCT02246218-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02246218-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.60.3130.832wilson
Risk in group 20.6880.4440.858wilson
Risk difference, group 1 minus group 2-0.0875-0.4220.249newcombe hybrid score
Risk ratio, group 1 over group 20.8730.4771.6log
Odds ratio, group 1 over group 20.6820.1313.55log
Number needed to treat, for one fewer participant with a serious adverse event on RAVICTI: Age 2 Months to < 2 Years than on RAVICTI: Age 0 to <2 Months11.4from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1RAVICTI: Age 2 Months to < 2 Years
Participants age 2 months to \< 2 years received RAVICTI Oral Liquid administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
610EG000
Group 2RAVICTI: Age 0 to <2 Months
Participants age 0 to \< 2 months received RAVICTI Oral Liquid administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
1116EG001

Harm

What it counts
Total, serious adverse events
Time frame
From the first dose of study treatment through 30 days after the final dose (mean [SD] duration of treatment was 9.13 [6.838] months for Cohort of 2 Months to <2 Years Participants and 10.67 [6.142] months for Cohort of 0 Months to <2 Months Participants).

Source ClinicalTrials.gov

Trial

Title
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
NCT number
NCT02246218
Phases
PHASE4
Conditions
Urea Cycle Disorder
Interventions
RAVICTI
Lead sponsor
Amgen
Results first posted
2019-03-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02246218-sae